Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Web Exclusives

Jemperli a New Immunotherapy Approved for All Patients with dMMR Solid Tumors
Web Exclusives — December 14, 2021
On August 17, 2021, the FDA accelerated the approval of Jemperli (dostarlimab-gxly; from GlaxoSmithKline) injection, an immunotherapy and a PD-1 inhibitor, for the treatment of all adults with recurrent (coming back) or advanced mismatch repair-deficient (dMMR) solid tumors, including lung cancer, that progressed during or after systemic therapy and for whom there are no satisfactory alternative treatment options. Read More ›

Reasons for Optimism for Patients with Cancer Facing Another Winter with COVID-19
Web Exclusives — December 1, 2021
Although we are entering another winter with the ongoing prevalence of the coronavirus, we have come a long way since the initial outbreak. Here are some reasons for patients to be optimistic for the season. Read More ›

Combining Targeted Therapies in CLL
Web Exclusives — November 17, 2021
The combination of acalabrutinib, venetoclax, and obinutuzumab has been shown to be an active regimen in previously untreated patients with CLL. Read More ›

A Comprehensive Analysis of COVID-19 in Patients with CLL
Web Exclusives — November 17, 2021
During the first 13 months of the pandemic, COVID-19 continued to result in high hospitalization rates among patients with CLL. Read More ›

Infections in Patients with CLL Receiving Ibrutinib
Web Exclusives — November 17, 2021
Identifying the risk factors for infection may allow preventive measures to be taken to protect patients. Read More ›

Measuring Treatment Adherence to Oral Therapies in Patients with CLL
Web Exclusives — November 17, 2021
Oral targeted therapies have revolutionized treatment for patients with CLL but ensuring that they are taken as prescribed is crucial to achieving optimal outcomes. Read More ›

Recent Regulation of Copay Adjustment Programs
Web Exclusives — November 17, 2021
Copay assistance coupons and copay adjustment programs put patients in the middle of healthcare cost-saving measures. Read More ›

Welcome to the Multiple Myeloma Resource Navigator for Patients
Web Exclusives — November 16, 2021
This publication was created together with leading patient advocates who shared their experiences and insights, in the hope that it will help you connect with patient organizations and resources as you and your care partners navigate through your diagnosis and treatment. These patient organizations provide education and support to promote your health and well-being, and help with practical matters, logistics, and financial and legal concerns. Read More ›

Why Every Patient with Cancer Needs a Strong Support System
Web Exclusives — November 1, 2021
Every person with cancer can benefit from a support system that can help manage the physical and emotional aspects of cancer care, as well as help with daily struggles. Read More ›

A Look at First-Line CLL Treatment in 2021
Web Exclusives — October 25, 2021
Currently, many effective, well-tolerated treatments exist, with high expectations for new drugs and regimens to be developed and approved in the near future. Read More ›

Page 5 of 26